Skip to main content

Peer Review reports

From: A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

Original Submission
4 Oct 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
1 Dec 2021 Reviewed Reviewer Report
13 Jan 2022 Reviewed Reviewer Report
24 Feb 2022 Author responded Author comments - Maria A Pantaleo
Resubmission - Version 4
24 Feb 2022 Submitted Manuscript version 4
14 Mar 2022 Author responded Author comments - Maria A Pantaleo
Resubmission - Version 5
14 Mar 2022 Submitted Manuscript version 5
15 Mar 2022 Author responded Author comments - Maria A Pantaleo
Resubmission - Version 6
15 Mar 2022 Submitted Manuscript version 6
21 Mar 2022 Reviewed Reviewer Report
22 Mar 2022 Reviewed Reviewer Report
2 Apr 2022 Author responded Author comments - Maria A Pantaleo
Resubmission - Version 7
2 Apr 2022 Submitted Manuscript version 7
Publishing
5 Apr 2022 Editorially accepted
6 May 2022 Article published 10.1186/s12885-022-09610-4

You can find further information about peer review here.

Back to article page